Requiring an amyloid-β1-42 biomarker for p... [Alzheimers Dement. 2011] - PubMed

Supplemental Content

Save items

Related citations in PubMed

Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. [Alzheimers Dement. 2010]
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
Schneider LS, Kennedy RE, Cutter GR, Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement. 2010 Sep; 6(5):367-77.
Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. [Neurobiol Aging. 2010]
Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.
Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB, Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging. 2010 Aug; 31(8):1443-51, 1451.e1. Epub 2010 Jun 11.
Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away. [Harv Ment Health Lett. 2010]
Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away.
[No authors listed]Harv Ment Health Lett. 2010 Nov; 27(5):1-3.
Review Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease? [Recent Pat CNS Drug Discov. 2008]
Review Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?
Zetterberg H. Recent Pat CNS Drug Discov. 2008 Jun; 3(2):109-11.
Review Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. [Drugs Today (Barc). 2007]
Review Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
Marksteiner J, Hinterhuber H, Humpel C. Drugs Today (Barc). 2007 Jun; 43(6):423-31.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild c...
Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
Alzheimers Dement. 2011 Mar ;7(2):245-6; author reply 247-9. doi: 10.1016/j.jalz.2010.12.013.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Comment on

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information